Humans are infected by Mycobacterium tuberculosis (MTB), the cause of tuberculosis (TB), primarily by inhaling aerosolized bacteria. Most individuals require adaptive T cell immunity to control MTB. The hallmark of this host-pathogen interaction is that, despite T cell immunity's control of bacillary growth, T cells do not eradicat MTB. Thus T cells and infected antigen presenting cells (APC) are not only central for control of MTB but also targets of its immune evasion strategies. Our studies have demonstrated that MTB interferes with T cell recognition of infected cells. We have used a strategy starting with MTB fractions followed by purification of MTB molecules that directly affect T cell function or antigen processing. Once an MTB molecule is identified, the molecular mechanism is determined. To date, we have identified 4 MTB mechanisms that affect T cell function: 2 inhibit and 2 activate human T cells. PIM and Rv2468c interact with VLA-5 on T cells to induce adhesion to fibronectin;lipoproteins can co-stimulate T cells through TLR-2. In contrast MTB lipoproteins through TLR-2 inhibit MHC-II antigen processing by macrophages;and (our most recent discovery) ManLAM inhibits proximal T cell receptor signaling (TCR) in a TLR-2 independent manner. Inhibition of TCR signaling by ManLAM, the most recent mechanism that we have discovered, forms the focus of this competing renewal application for the following reasons. First, ManLAM is one of the most abundant glycolipids in the MTB cell wall. Second, ManLAM travels outside the phagosome to interact with host cells. Third, ManLAM is readily found in exosomes and microvesicles produced by MTB infected cells, providing a mechanism for direct delivery to T cells. Fourth, ManLAM inserts into host cell membranes. Fifth, ManLAM represents the most direct mechanism so far for interdicting T cell response during both latent MTB infection and active TB. Thus ManLAM's interference with TCR signaling represents a second major mechanism for interfering with T cell activation and that sensitivity to this inhibitoy effect may affect one's ability to control or eliminate latent bacilli.
The aims are:
Aim 1. To determine the molecular mechanism of inhibition of TCR signaling by ManLAM in terms of how ManLAM is delivered to T cells, how and where it inserts in the T cell membrane and how it interferes with TCR function and T cell-APC conjugate formation, and ManLAM's structural requirements for inhibition.
Aim 2. To determine the functional consequences of ManLAM inhibition of CD4+ T cell activation in terms of recovery of inhibition, induction of apoptosis or anergy, differential effects on non-CD4+ T cells and synergy with inhibition of MHC-II antigen processing.
Aim 3. To determine the ability of ManLAM to inhibit T cell responses to MTB in vivo using the murine MTB infection model and determining if there is variable sensitivity to ManLAM among humans.

Public Health Relevance

Understanding how M. tuberculosis, the cause of human tuberculosis (TB), evades the immune system controlled by T cells so that it persists in a dormant state to cause disease many years later, is essential not only for host-pathogenesis studies but also for development and testing of new T cell vaccines for TB. Variable sensitivity to M. tuberculosis'T cell immune evasion strategies may be a factor in susceptibility to progression from M. tuberculosis infection to disease and in a person's ability to effectively clea M. tuberculosis bacilli with drug therapy.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01AI027243-25
Application #
8646838
Study Section
Host Interactions with Bacterial Pathogens Study Section (HIBP)
Program Officer
Lacourciere, Karen A
Project Start
Project End
Budget Start
Budget End
Support Year
25
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Li, Qing; Ding, Xuedong; Thomas, Jeremy J et al. (2012) Rv2468c, a novel Mycobacterium tuberculosis protein that costimulates human CD4+ T cells through VLA-5. J Leukoc Biol 91:311-20
Simmons, Daimon P; Wearsch, Pamela A; Canaday, David H et al. (2012) Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J Immunol 188:3116-26
Mahon, Robert N; Sande, Obondo J; Rojas, Roxana E et al. (2012) Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cell Immunol 275:98-105
Lancioni, Christina L; Li, Qing; Thomas, Jeremy J et al. (2011) Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2. Infect Immun 79:663-73
Ramachandra, Lakshmi; Qu, Yan; Wang, Ying et al. (2010) Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation. Infect Immun 78:5116-25
Drage, Michael G; Tsai, Han-Chun; Pecora, Nicole D et al. (2010) Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nat Struct Mol Biol 17:1088-95
Simmons, Daimon P; Canaday, David H; Liu, Yi et al. (2010) Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J Immunol 185:2405-15
Harding, Clifford V; Boom, W Henry (2010) Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 8:296-307
Drage, Michael G; Pecora, Nicole D; Hise, Amy G et al. (2009) TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol 258:29-37
Lancioni, Christina L; Thomas, Jeremy J; Rojas, Roxana E (2009) Activation requirements and responses to TLR ligands in human CD4+ T cells: comparison of two T cell isolation techniques. J Immunol Methods 344:15-25

Showing the most recent 10 out of 64 publications